Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 12:47 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 529–552 of 553 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Block performed Clear all

Conditions: Benign Prostatic Hyperplasia, Lower Urinary Tract Symptoms
Interventions: Prostatic artery embolization; Device
Lead sponsor: Andrew Picel; Other
Eligibility: 45 Years to 85 Years · Male only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Palo Alto, California

Conditions: Hysterectomy
Interventions: Bupivacaine Hydrochloride 0.25% Injection Solution; Drug
Lead sponsor: Jon I. Einarsson; Other
Eligibility: 18 Years and older · Female only
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 2
States / cities: Boston, Massachusetts

Conditions: Shoulder Pain
Interventions: Superficial Cervical Plexus Block, Bupivacaine; Procedure · Drug
Lead sponsor: University of Washington; Other
Eligibility: 18 Years to 75 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Osteoarthritis, Knee
Interventions: Genicular nerve radiofrequency ablation, Pain Management Radiofrequency Kit; Procedure · Device
Lead sponsor: Millennium Pain Center; Other
Eligibility: 18 Years to 100 Years
Enrollment: 79 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 3
States / cities: Bloomington, Illinois • Decatur, Illinois • Peoria, Illinois

Conditions: Branch Retinal Vein Occlusion
Interventions: Brolucizumab 6 mg, Aflibercept 2 mg, Sham injection; Drug · Other
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 450 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 26
States / cities: Phoenix, Arizona • Mountain View, California • Santa Barbara, California + 21 more

Conditions: Cancer of Bladder
Interventions: Obturator block, Neuromuscular block; Drug
Lead sponsor: University of Florida; Other
Eligibility: 18 Years to 90 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Osteoarthritis of Hip, Regional Anesthesia, Other Acute Postoperative Pain, Total Hip Arthroplasty, Peripheral Nerve Block, Lumbar Plexus Nerve Block, Parasacaral (Sciatic) Nerve Block
Interventions: Continuous Lumbar Plexus Block, Parasacral Nerve Block, Ropivacine 0.2%, Bupivacaine 0.0625%; Procedure · Drug
Lead sponsor: Rita Merman; Other
Eligibility: 18 Years to 75 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Blood Flow Restriction (BFR) Training Effects, Arterial Stiffness, Blood Pressure, Muscle Morphology, Perceptions
Interventions: Delfi Training Device; Device
Lead sponsor: Teri Herberger; Other
Eligibility: 18 Years to 40 Years
Enrollment: 27 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025
U.S. locations: 1
States / cities: Salisbury, Maryland

Conditions: Stroke
Interventions: No aortic clamping, partial occluding clamp, single cross clamp, cross clamp and partial occluding clamp; Procedure
Lead sponsor: Emory University; Other
Eligibility: 18 Years and older
Enrollment: 193 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2016
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Ocular Rosacea, Dry Eye
Interventions: Intense Pulsed Light Treatment (IPL), Meibomian Gland Expression; Device · Procedure
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 100 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Scottsdale, Arizona

Conditions: Postoperative Pain
Interventions: Ropivacaine; Drug
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years to 80 Years
Enrollment: 52 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2020
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Intestinal Anastomosis Complication
Interventions: Magnamosis; Device
Lead sponsor: Michael Harrison; Other
Eligibility: 18 Years to 60 Years
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 2
States / cities: San Francisco, California

Conditions: Liver Cancer
Interventions: sorafenib tosylate, HACE : Doxorubicin Hydrochloride and Mitomycin C, laboratory biomarker analysis; Drug · Other
Lead sponsor: Rutgers, The State University of New Jersey; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 1
States / cities: Newark, New Jersey

Conditions: Post Operative Pain, Nausea and Vomiting, Postoperative, Opioid Use
Interventions: bilateral superficial cervical plexus blocks and local wound infiltration, placebo injection and local wound infiltration; Procedure
Lead sponsor: University of California, Davis; Other
Eligibility: 18 Years to 99 Years
Enrollment: 74 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Sacramento, California

Conditions: Solid Tumor
Interventions: Atezolizumab, GDC-0919; Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 158 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 10
States / cities: Scottsdale, Arizona • Santa Monica, California • Aurora, Colorado + 6 more

Conditions: Fine Needle Aspiration, Pancreatic Mass
Interventions: EUS-FNA with ROSE, EUS-FNB without ROSE; Diagnostic Test
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2023
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Peripheral Vascular Diseases, Hyperglycaemia (Diabetic), Hypertension, Coronary Artery Disease, Pulmonary Disease, Chronic Obstructive
Interventions: Peripheral nerve block, Intravenous Sedatives, Lateral femoral cutaneous nerve blocks, Obturator nerve blocks; Procedure · Drug
Lead sponsor: University of Florida; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2024
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Atrial Fibrillation
Interventions: 4D ICE Adjunct Imaging; Device
Lead sponsor: The Cleveland Clinic; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Cleft Palate Children
Interventions: Ultrasound-guided bilateral suprazygomatic maxillary nerve block, Local anesthetic infiltration of the palate; Procedure
Lead sponsor: Ann & Robert H Lurie Children's Hospital of Chicago; Other
Eligibility: 9 Months to 2 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2025
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Diabetes (DM)
Interventions: Exendin-9 is a 30 amino acid peptide that is an established competitive antagonist of the GLP-1 receptor. Subjects will receive exendin-9 by intravenous infusion at a rate of 600 pmol/kg/min, Dexamethasone, Dextrose 20% solution; Drug
Lead sponsor: David D'Alessio, M.D.; Other
Eligibility: 18 Years to 60 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Prostate Cancer
Interventions: SipT Treatment, Ipilimumab; Drug
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older · Male only
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2020
U.S. locations: 2
States / cities: San Francisco, California • Houston, Texas

Conditions: Burns
Interventions: Regional nerve block, Catheter; Procedure
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 2 Years to 21 Years
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2013
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: General Surgery
Interventions: Sugammadex, Placebo; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 100 Years
Enrollment: 260 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 2
States / cities: Jacksonville, Florida • Houston, Texas

Conditions: Congenital Diaphragmatic Hernia, Pulmonary Hypoplasia
Interventions: GoldBAL2 Detachable Balloon and BALTACCIBDPE100 Delivery Catheter; Device
Lead sponsor: Children's Hospital of Philadelphia; Other
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2027
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Search by objective public record fields.

Prostatic Artery Embolization for the Treatment of Symptomatic Benign Prostatic Hyperplasia (BPH)

RCT Superior Hypogastric Block During LH

Superficial Cervical Plexus Block for Shoulder Pain After Lung Surgery

Efficacy of Cooled and Monopolar Radiofrequency Ablation of the Geniculate Nerves for the Treatment of Chronic Osteoarthritic Knee Pain

Assessing the Efficacy and Safety of Brolucizumab Versus Aflibercept in Patients With Visual Impairment Due to Macular Edema Secondary to Branch Retinal Vein Occlusion

Comparison of Obturator Nerve Blockade and Neuromuscular Blockade

Continuous Lumbar Plexus Block With and Without Parasacral Block in Patients Undergoing Total Hip Replacement

Effect of Limb Occlusion Pressure Attainment on Cardiovascular, Perceptual, and Performance Responses

Stroke Study: Operative Strategies to Reduce Cerebral Embolic Events During Coronary Artery Bypass Surgery

Efficacy of IPL Treatment of Dry Eye and Ocular Rosacea

Adductor Canal Mid-thigh and Adductor Canal Distal Thigh: Is Cutaneous Sensory Blockade Similar Among Block Techniques?

Magnamosis First-in-human Study of Feasibility and Safety

Sorafenib Tosylate Before and After Hepatic Arterial Chemoembolization With Doxorubicin Hydrochloride and Mitomycin C in Treating Patients With Localized Liver Cancer That Cannot Be Removed by Surgery

ENDOblock: Bilateral Superficial Cervical Blocks With Local Wound Infiltration in Thyroid Surgery

A Study of GDC-0919 and Atezolizumab Combination Treatment in Participants With Locally Advanced or Metastatic Solid Tumors

EUS FNB Versus FNA With On-Site Cytopathology in Solid Pancreatic Masses

Peripheral Nerve Blocks for Above-the-knee Amputations

Evaluation of 4D Intracardiac Echocardiography (ICE) During Structural Heart and Electrophysiology Procedures

Suprazygomatic Maxillary Nerve Block in Cleft Palate Outcomes

Role of Alpha-to-beta Cell Communication to Adapt Insulin Secretion to Insulin Resistance.

Sipuleucel-T With Immediate vs. Delayed Cytotoxic T-Lymphocyte-Associated Protein 4 (CTLA-4) Blockade for Prostate Cancer

Ultrasound-Guided Block of the Lateral Femoral Cutaneous Nerve in Pediatric Patients

Sugammadex vs Placebo to Prevent Residual Neuromuscular Block

Fetoscopic Endoluminal Tracheal Occlusion in Severe Left Congenital Diaphragmatic Hernia